Jonathan is a partner at Saisei Ventures, a leading healthcare focused venture capital firm. Jonathan is an early-stage investor in the field of regenerative medicine and advanced therapies, with particular expertise with cell-based therapies and gene-modified cells. Previously, Jonathan was at the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto, Canada, overseeing early-stage investment and portfolio management activities at the firm. Prior to joining CCRM, Jonathan supported new company spin-out and technology licensing activities at the Universite de Montreal. Jonathan also served as the Executive Director of a Genome Canada Large Scale Applied Research Project called the Leucegene Project, which explored the genetic hallmarks and associated chemical sensitivities of acute myeloid leukemia subtypes.
Jonathan received his Ph.D. from McGill University, studying germ line stem cell biology. Jonathan conducted post-doctoral studies at the Universite de Montreal, where he studied the biology of hematopoietic and leukemic stem cells, resulting in several manuscripts and patents. In 2016, Jonathan earned his MBA from the John Molson School of Business at Concordia University in Montreal, Canada.
Jonathan is attending / has attended:
Venture Summit Virtual Connect | Global 21